Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- Semaglutide can reduce psoriasis severity mainly by driving weight loss that lowers inflammatory cytokines, with possible direct effects on NF-κB and Th17 pathways.1
- Observational studies show meaningful PASI score improvements, especially in patients who lose more than 10% of their body weight and improve metabolic health.1
- Semaglutide is not FDA-approved for psoriasis and is used off-label as an add-on to standard dermatologic treatments, not a replacement.
- Stopping semaglutide without a plan often leads to weight regain and inflammatory rebound, so supervised maintenance or transition protocols matter.
- At Mirror Plastic Surgery, Ellie Pranckevicius, FNP-BC, provides personalized, lab-informed GLP-1 protocols with ongoing support. Book a consultation to see whether this approach fits your health profile.
How Semaglutide Fits into Psoriasis Care
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1, suppresses appetite, slows gastric emptying, and improves insulin sensitivity. Psoriasis is a chronic immune-mediated inflammatory skin disease driven mainly by dysregulated IL-17, IL-23, and TNF-α signaling, which produces thick, scaly plaques. Obesity amplifies psoriasis severity because adipose tissue secretes pro-inflammatory adipokines, including leptin and resistin, while suppressing adiponectin, directly fueling the IL-17/IL-23 and TNF-α axes that drive skin inflammation.
A review of GLP-1 receptor agonists in psoriasis reports meaningful reductions in PASI scores across studies, with the largest gains in patients who lost more than 10% of body weight.1 This weight-loss threshold appears consistently across study designs and helps explain why retrospective analyses of semaglutide-treated patients with co-existing psoriasis have shown PASI 75 responses in some patients, with particularly strong responses in the obese subgroup.1 The metabolic improvements that accompany weight loss also appear in a 12-week open-label study of patients with obesity, psoriasis, and type 2 diabetes taking concurrent metformin, where semaglutide reduced PASI scores while also improving DLQI scores, BMI, LDL cholesterol, and C-reactive protein levels.1 Prospective studies of patients with psoriasis and obesity further support that semaglutide can lower PASI scores.1
In a case report of a patient with severe psoriasis and type 2 diabetes who had previously failed topical therapy and adalimumab, semaglutide treatment reduced BMI and PASI score.1 The current evidence base remains limited to observational cohorts, retrospective studies, and small prospective analyses. The ongoing SEMAPSO trial (NCT07401992), a randomized, triple-blind, placebo-controlled study enrolling 62 participants with plaque psoriasis plus overweight or obesity and/or type 2 diabetes, is designed to provide more rigorous data. Investigators are measuring PASI at baseline and weeks 4, 8, and 12 alongside systemic inflammatory and metabolic biomarkers, and results are still pending.
No GLP-1 receptor agonist, including semaglutide, is currently FDA-approved for the treatment of psoriasis. As the National Psoriasis Foundation Medical Board Chair Andrew Blauvelt, MD, MBA, states, “GLP-1 RA use is not for the treatment of psoriasis per se; it’s for the treatment of obesity and overweight, which influences the response of the psoriasis drugs.”
How GLP-1 Medications May Improve Psoriasis
Two mechanistic pathways explain how GLP-1 medications may help psoriasis.1 The primary and better-established pathway is indirect: weight loss reduces adipose-derived secretion of IL-6, TNF-α, and IL-17, which lowers the inflammatory burden that drives psoriatic plaques. A secondary pathway involves direct immunomodulatory effects, including suppression of NF-κB-driven cytokine production, reduced macrophage M1 polarization, and attenuated Th17 differentiation. GLP-1 receptors are expressed on dendritic cells, macrophages, and T-lymphocytes, which provides a biologic basis for direct anti-inflammatory signaling independent of weight loss, although the clinical magnitude of this direct effect remains under active investigation.
Research on liraglutide in patients with type 2 diabetes and plaque psoriasis has found lower PASI scores after treatment and indicates that liraglutide can reduce expression of IL-17, IL-23, and TNF-alpha.1 The National Psoriasis Foundation medical board concludes that GLP-1 receptor agonists should be considered as adjunctive therapy for psoriasis patients with comorbid metabolic disorders, citing clinical evidence of improvements in skin severity, quality of life, and systemic inflammation. In the TOGETHER-PsO trial, 27.1% of patients with moderate-to-severe psoriasis and obesity who received ixekizumab plus tirzepatide achieved both 10% weight loss and 100% PASI improvement at 36 weeks, compared to 5.8% on ixekizumab alone.1
Patients frequently report subjective improvements in joint pain and general inflammatory symptoms alongside skin changes.1 These reports align with the cytokine-reduction data and with a TriNetX real-world cohort study that found a reduction in risk of developing psoriatic arthritis within one year.1 To place semaglutide in context with newer GLP-3R compounds and adjunct peptides, the following table summarizes how these options differ in mechanism, evidence, and tolerability.
| Agent | Primary Mechanism in Psoriasis Context | Reported PASI Impact | GI Side Effect Profile |
|---|---|---|---|
| Semaglutide (GLP-1 RA) | Weight-loss-mediated cytokine reduction, direct NF-κB and Th17 suppression | PASI reductions in metabolic comorbidity cohorts | Nausea, vomiting, diarrhea, constipation, typically managed with dose escalation |
| GLP-3R Compounding (newer generation) | Broader metabolic targets including insulin resistance and cardiovascular risk, with similar cytokine pathway modulation | Psoriasis-specific PASI data not yet established in published trials | Reported to have fewer GI symptoms than older GLP-1 formulations, with lower reported muscle-wasting risk |
| BPC-157 / TB-500 / KPV (adjunct peptides) | Systemic and gut inflammation reduction, soft tissue repair, and gut microbiome modulation (KPV) | No published PASI trial data, used adjunctively for inflammatory load reduction | No established GI side effect profile comparable to the GLP-1 class in published literature |
These mechanistic and tolerability differences guide initial protocol design, and they also shape planning for maintenance, adjustment, or discontinuation over time.
What Happens If I Stop Semaglutide?
Stopping semaglutide often leads to partial weight regain and reversal of metabolic gains.1 A 2026 systematic review and meta-analysis found that discontinuation of GLP-1 receptor agonists is associated with weight regain of about 60% of lost weight within one year, with cardiometabolic benefits reversing in parallel. Glycemic, blood pressure, and lipid parameters are modeled to return to baseline within about 12 months, and HbA1c within 12 to 18 months. The same review classifies GLP-1 discontinuation as a high-risk clinical transition rather than a treatment endpoint.
Real-world data from a Cleveland Clinic retrospective cohort study of 7,938 adults show a more variable picture. Patients treated for obesity lost an average of 8.4% of body weight before discontinuation and regained only 0.5% one year later on average, partly because 27% switched to a different medication and 20% restarted the original drug within 12 months. Among obesity-treated patients, 55% gained weight after discontinuation while 45% maintained or continued losing weight. For psoriasis specifically, inflammatory marker rebound is expected to track weight regain, so patients who discontinue without a structured transition plan are likely to see psoriasis symptoms move back toward baseline.1 Supervised maintenance protocols or planned transitions to adjunct peptide therapies provide an evidence-informed way to preserve gains.
Combining Semaglutide with Other Psoriasis Treatments
The National Psoriasis Foundation medical board positions GLP-1 receptor agonists as adjunctive therapy alongside standard dermatologic management, not as a replacement. The TOGETHER-PsO trial shows that biologic response improves when weight is reduced at the same time, as patients on ixekizumab plus tirzepatide achieved PASI 100 at nearly five times the rate of those on ixekizumab alone.1 The SEMAPSO trial is evaluating oral semaglutide combined with topical corticosteroid and calcipotriol, with results pending.
GLP-1 receptor agonists should not replace standard psoriasis skin care plans and are positioned only as an adjunct to regular dermatologic management. Collaboration between dermatology, primary care, and endocrinology is recommended when GLP-1 receptor agonists are considered for patients with both inflammatory skin disease and metabolic conditions.
At Mirror Plastic Surgery, Ellie builds custom stacks that may layer GLP-1 or GLP-3R protocols with adjunct peptides such as BPC-157 for systemic inflammation, TB-500 for soft tissue repair, GHK-Cu for skin collagen support, or KPV for gut microbiome inflammation, depending on each patient’s lab results, metabolic profile, and psoriasis severity. These combinations aim to reduce inflammatory load from multiple angles while supporting the metabolic changes that make primary psoriasis therapies more effective.
Medically Supervised Protocol at Mirror Plastic Surgery
Every patient begins with a 30 to 60 minute consultation with Ellie Pranckevicius that covers full medical history, current medications, and specific health goals. For weight-related or inflammatory conditions, lab panels that include thyroid, liver, kidney, diabetes markers, and hormone panels are reviewed or ordered. From this foundation, Ellie designs a custom peptide stack and titration protocol tailored to the individual’s physiology.
Peptides are sourced from reputable providers with rigorous batch testing, which supports product quality, purity, and accurate dosage and clearly separates this approach from unverified online sources. Consultations, prescriptions, and ongoing support are available both in-person at Mirror’s St. Petersburg, Florida location and remotely across the United States, including Hawaii and Alaska. Ellie is available via text for ongoing questions, refill requests, and dose-escalation guidance, and scheduled telemedicine appointments provide structured reassessment at regular intervals. For patients who are also surgical candidates, peptide protocols can be integrated with post-operative recovery plans under Dr. Akash Chandawarkar’s oversight.
Book an appointment with Ellie to receive a personalized evaluation and lab-informed protocol tailored to your metabolic and skin health goals.
Risks, Limitations, and Regulatory Context
Common adverse effects of semaglutide include nausea, vomiting, diarrhea, constipation, and early satiety, and gradual dose escalation is the standard strategy to improve tolerability. Contraindications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, prior pancreatitis, significant gallstone disease, severe gastroparesis, and pregnancy or planned conception.
A 2026 FAERS database analysis published in the Journal of Drugs in Dermatology found cutaneous adverse events reported with GLP-1 receptor agonists. Separately, dermatologic adverse events reported include bullous pemphigoid, morbilliform eruptions, and fixed drug eruptions. Patients should also be counseled on the possibility of telogen effluvium, accelerated facial volume loss, and skin laxity during rapid weight reduction. A possible association with nonarteritic anterior ischemic optic neuropathy (NAION) has been raised in observational analyses, so patients should seek urgent ophthalmic evaluation for new painless vision loss.
The National Psoriasis Foundation primer recommends that only FDA-approved GLP-1 RAs be prescribed and that compounded or nonstandard formulations be avoided due to risks of variable potency, contamination, and dosing errors. Monitoring should include baseline and serial measurements of weight, BMI, HbA1c, fasting glucose, lipid profile, PASI, and DLQI, with reassessment every 3 to 6 months and brief visits at each dose escalation. Mirror Plastic Surgery’s protocol incorporates these monitoring benchmarks as standard practice.
GLP-3R compounds represent a newer generation with a reported reduction in GI side effects and lower muscle-wasting risk compared to older GLP-1 formulations and may be appropriate for patients who experience intolerable GI symptoms on semaglutide. Ellie evaluates each patient’s tolerance and response at every follow-up to decide whether a protocol adjustment or transition is warranted.
Frequently Asked Questions
Is semaglutide FDA-approved for psoriasis?
No. Semaglutide is FDA-approved for chronic weight management and type 2 diabetes. Its use in psoriasis is off-label, meaning it is not prescribed specifically to treat psoriasis but rather to address the obesity or metabolic dysfunction that amplifies psoriasis severity. Any use in this context should be supervised by a qualified clinician who can monitor both metabolic and dermatologic outcomes.
Who is most likely to see psoriasis improvement on semaglutide?
Current evidence consistently points to patients with a BMI of 30 or higher, or those with comorbid type 2 diabetes or insulin resistance, as the subgroup with the strongest PASI responses. The mechanism is largely tied to weight-loss-driven reductions in adipose-derived cytokines. Patients without significant metabolic comorbidity have a less established evidence base for benefit, and realistic expectations should be set during a clinical consultation that includes lab review.
Can semaglutide replace my current psoriasis medication?
No. The National Psoriasis Foundation and dermatology experts position GLP-1 receptor agonists as adjunctive therapy alongside, not instead of, standard psoriasis treatments such as topicals or biologics. The evidence suggests that semaglutide makes existing psoriasis therapies work better, particularly in patients who achieve meaningful weight loss, rather than functioning as a standalone treatment for the skin condition itself.
What monitoring is needed while on a GLP-1 protocol for psoriasis?
A comprehensive monitoring plan includes baseline and periodic measurements of weight, BMI, HbA1c, fasting glucose, lipid profile, liver and kidney function, PASI scores, and quality-of-life measures. Reassessment is recommended every 3 to 6 months, with additional check-ins at each dose escalation. At Mirror Plastic Surgery, Ellie conducts this monitoring as part of the ongoing concierge protocol, with direct text access between scheduled appointments for any emerging concerns.
What happens to psoriasis symptoms if I stop semaglutide?
Inflammatory markers and psoriasis symptoms are expected to track weight regain after discontinuation. Randomized trial data show weight regain of about 60% of lost weight within one year of stopping GLP-1 therapy, although real-world outcomes vary depending on whether patients transition to another treatment or adopt structured lifestyle interventions. A supervised discontinuation plan, which may include transitioning to adjunct anti-inflammatory peptides or a maintenance protocol, is the recommended approach to preserving the skin and metabolic improvements achieved during treatment.
Summary
The evidence reviewed here supports semaglutide as a metabolic tool that can meaningfully improve psoriasis severity in patients with obesity or metabolic dysfunction. Most benefits appear to flow through weight-loss-driven cytokine reduction, with possible direct immunologic effects still under study. Observational data and ongoing trials align with the National Psoriasis Foundation’s position that GLP-1 therapy should serve as an adjunct rather than a replacement for standard psoriasis care. For patients considering this approach, key decision points include metabolic eligibility, clear expectations about mechanism and timeline, and a structured plan for monitoring, maintenance, or discontinuation.
Book an appointment with Ellie at Mirror Plastic Surgery to receive a comprehensive lab review and a personalized GLP-1 or adjunct peptide protocol designed for your specific metabolic and skin health profile.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Semaglutide is not FDA-approved for the treatment of psoriasis. All treatment decisions should be made in consultation with a qualified healthcare provider based on individual health history, lab results, and clinical assessment. Results vary significantly between individuals. Peptide therapies discussed herein are not FDA-regulated; quality, safety, and appropriateness depend on the source and clinical supervision. Inter-individual variability in response, tolerance, and outcomes is expected and should be discussed with your provider before initiating any protocol.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
